MASH

Poxel SA, facing insolvency proceedings, has overhauled its board and leadership. The entire existing board resigned, replaced by Sophie Jacq Lapointe (Chairman), Nicolas Trouche (CEO), Amit Kohli, and Alexandre Bragadir. Trouche succeeds Thomas Kuhn as CEO. Lapointe brings pharmaceutical commercialization expertise, while Trouche specializes in restructuring. Kohli has expertise in diabetes therapies and Bragadir in healthcare financing. Poxel’s focus remains on MASH and rare metabolic disorder treatments, including PXL065 and PXL770, and its diabetes drug TWYMEEG®. The new leadership aims to navigate restructuring and secure funding.

Genflow Biosciences (GENFF) secured a €4 million non-dilutive grant from Belgium’s Wallonia Region to advance GF-1002, its gene therapy candidate for Metabolic Associated Steatohepatitis (MASH). The grant covers a three-year development program aligned with Genflow’s clinical roadmap. While initial disbursement awaits administrative procedures, the GF-1002 program continues without interruption. Genflow highlights that all project-related expenses incurred in 2025 will be eligible under the grant’s terms.